Literature DB >> 12685881

Characteristics of erythema migrans in Borrelia afzelii and Borrelia garinii infections.

Sten-Anders Carlsson1, Hans Granlund, Christian Jansson, Dag Nyman, Peter Wahlberg.   

Abstract

Erythema migrans is the most common manifestation of stage I Lyme borreliosis. This study investigated the relation between the subspecies of Borrelia burgdorferi involved, the time of development and the appearance of the manifestation. The study comprised 33 cases of erythema migrans yielding B. burgdorferi sensu lato by culture of skin biopsy. The species was determined by polymerase chain reaction analysis of the cultivated spirochaetes. In 22 of the cases, B. afzelii was demonstrated, whereas 11 yielded growth of B. garinii. All 11 erythemas associated with B. garinii were homogeneous, whereas 20 of the 22 associated with B. afzelii were annular. The garinii erythemas developed more rapidly, and were generally larger than the afzelii erythemas. The observations call for comparison with other geographical areas with similar, and with different, borrelial infection spectra.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12685881     DOI: 10.1080/0036554021000026978

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  11 in total

1.  Lyme neuroborreliosis and bird populations in northern Europe.

Authors:  Atle Mysterud; Dieter J A Heylen; Erik Matthysen; Aïda Lopez Garcia; Solveig Jore; Hildegunn Viljugrein
Journal:  Proc Biol Sci       Date:  2019-05-29       Impact factor: 5.349

2.  Increased incidence of Lyme borreliosis in southern Sweden following mild winters and during warm, humid summers.

Authors:  L Bennet; A Halling; J Berglund
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-07       Impact factor: 3.267

3.  Borrelia burgdorferi RST1 (OspC type A) genotype is associated with greater inflammation and more severe Lyme disease.

Authors:  Klemen Strle; Kathryn L Jones; Elise E Drouin; Xin Li; Allen C Steere
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

4.  Clinical appearance of erythema migrans caused by Borrelia afzelii and Borrelia garinii--effect of the patient's sex.

Authors:  Louise Bennet; Carl-Johan Fraenkel; Ulf Garpmo; Anders Halling; Mikael Ingman; Katharina Ornstein; Louise Stjernberg; Johan Berglund
Journal:  Wien Klin Wochenschr       Date:  2006-09       Impact factor: 1.704

5.  Borrelia burgdorferi stimulates macrophages to secrete higher levels of cytokines and chemokines than Borrelia afzelii or Borrelia garinii.

Authors:  Klemen Strle; Elise E Drouin; Shiqian Shen; Joseph El Khoury; Gail McHugh; Eva Ruzic-Sabljic; Franc Strle; Allen C Steere
Journal:  J Infect Dis       Date:  2009-12-15       Impact factor: 5.226

6.  DNA Methylation by Restriction Modification Systems Affects the Global Transcriptome Profile in Borrelia burgdorferi.

Authors:  Timothy Casselli; Yvonne Tourand; Adam Scheidegger; William K Arnold; Anna Proulx; Brian Stevenson; Catherine A Brissette
Journal:  J Bacteriol       Date:  2018-11-26       Impact factor: 3.490

Review 7.  Outer surface protein polymorphisms linked to host-spirochete association in Lyme borreliae.

Authors:  Danielle M Tufts; Thomas M Hart; Grace F Chen; Sergios-Orestis Kolokotronis; Maria A Diuk-Wasser; Yi-Pin Lin
Journal:  Mol Microbiol       Date:  2019-02-27       Impact factor: 3.501

8.  Lyme Disease in Humans.

Authors:  Justin D Radolf; Klemen Strle; Jacob E Lemieux; Franc Strle
Journal:  Curr Issues Mol Biol       Date:  2020-12-11       Impact factor: 2.081

9.  Lyme borreliosis and Borrelia spielmanii.

Authors:  Vera Maraspin; Eva Ruzic-Sabljic; Franc Strle
Journal:  Emerg Infect Dis       Date:  2006-07       Impact factor: 6.883

10.  Differences in Genotype, Clinical Features, and Inflammatory Potential of Borrelia burgdorferi sensu stricto Strains from Europe and the United States.

Authors:  Tjasa Cerar; Franc Strle; Dasa Stupica; Eva Ruzic-Sabljic; Gail McHugh; Allen C Steere; Klemen Strle
Journal:  Emerg Infect Dis       Date:  2016-05       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.